These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9005589)

  • 1. [Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2].
    Vecchioli Scaldazza C
    Minerva Urol Nefrol; 1996 Dec; 48(4):203-6. PubMed ID: 9005589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylaxis of transitional cell carcinoma of the bladder G1-G2; pTa-pT1 with mitomycin C or interferon alpha-2a. Preliminary data].
    Vecchioli Scaldazza C
    Minerva Urol Nefrol; 1993 Sep; 45(3):117-21. PubMed ID: 8278878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
    Minervini R; Felipetto R; Viganò L; Pampaloni S; Fiorentini L
    Urol Int; 1996; 56(4):234-7. PubMed ID: 8776821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
    Boccardo F; Cannata D; Rubagotti A; Guarneri D; Decensi A; Canobbio L; Curotto A; Martorana G; Pegoraro C; Selvaggi F
    J Clin Oncol; 1994 Jan; 12(1):7-13. PubMed ID: 8270987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
    O'Brien T; Ray E; Singh R; Coker B; Beard R;
    Eur Urol; 2011 Oct; 60(4):703-10. PubMed ID: 21684068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
    Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
    Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
    Colombo R; Da Pozzo LF; Salonia A; Rigatti P; Leib Z; Baniel J; Caldarera E; Pavone-Macaluso M
    J Clin Oncol; 2003 Dec; 21(23):4270-6. PubMed ID: 14581436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical adjuvant therapy using mitomycin C.
    Islam MA; Bhuiyan ZH; Shameem IA
    Mymensingh Med J; 2006 Jan; 15(1):40-4. PubMed ID: 16467761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study.
    Sakamoto N; Naito S; Kumazawa J; Ariyoshi A; Osada Y; Omoto T; Fujisawa Y; Morita I; Yamashita H;
    Int J Urol; 2001 May; 8(5):212-6. PubMed ID: 11328420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
    Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
    J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
    Faraj K; Chang YH; Rose KM; Habermann EB; Etzioni DA; Blodgett G; Castle EP; Humphreys MR; Tyson Ii MD
    Can J Urol; 2019 Oct; 26(5):9922-9930. PubMed ID: 31629441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.
    De Nunzio C; Carbone A; Albisinni S; Alpi G; Cantiani A; Liberti M; Tubaro A; Iori F
    World J Urol; 2011 Aug; 29(4):517-21. PubMed ID: 21594708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.